Bioeq has in-licensed the exclusive global commercialization rights to FYB201 from the German biosimilar developer Formycon AG. "Unlocking the value of biologics with biosimilars is an important new frontier in drug development that offers patients safe and effective treatment options through more affordable alternatives to branded biological products that have lost their exclusivity rights," says Sven Dethlefs, PhD, Executive Vice President, Global Marketing & Portfolio and International Markets Commercial. "This collaboration expands Teva's biosimilar portfolio and again demonstrates the company's firm commitment to creating greater access to quality medications to help improve the lives of more patients." Commenting on the agreement, Nicola Mikulcik, Board Member at Bioeq, says, "We are proud of having secured Teva as our partner of choice for these markets.